Across TCGA pan-cancer cohorts, ZBTB8B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZBTB8B data layer compared with 29 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher ZBTB8B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB8B expression acts as an unfavorable survival marker.
COAD and LIHC are the cancer types where ZBTB8B Mutation most reproducibly stratifies survival.